Theravance Biopharma Inc

ACTIVE

C/O Maples Corporate Services Ltd, 加利福尼亚州圣马特奥县, California, Cayman Islandswww.theravance.comPublic251–500 employeesEstablished: 1996-01-01$410.0M

Also known as:

theravance, inc.

Clinical Trials

15 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1996

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

41.2%

Phase 2

5.9%

Phase 3

5.9%

Trial Status Distribution

Active, not recruiting

88.2%

Completed

11.8%

Clinical Trials

Trials sponsored by this organization (17)

Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD-4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease

Phase 1

Active, not recruiting

Feb 201362 participants

The effects of multiple doses of TD4208 for 7 days in COPD

Active, not recruiting

Dec 201260 participants

A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed with Chronic Obstructive Pulmonary Disease

Phase 2

Completed

interventional

May 201132 participants

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus - N/A

Phase 1

Active, not recruiting

Sep 2006746 participants

A Phase 3, Randomized, Double-Blind, Parallell-Group, Multinational Trial of Intravenous Telavancin versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections due to Methicillin-Resistant Staphylococcus aureus. - ATTAIN 2

Phase 1

Active, not recruiting

Aug 2006746 participants

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN 2) - ATTAIN 2

Active, not recruiting

Aug 2006750 participants

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN 2) - ATTAIN 2

Active, not recruiting

Jul 2006750 participants

A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia with a Focus on Patients with Infections Due to Methicillin-Resistant Staphylococcus aureus (ATTAIN 2) - ATTAIN 2

Phase 1

Active, not recruiting

May 2006757 participants

Page 1 of 3

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

Recent Approvals

News

No news articles found

Back to Organizations